Filing identity and reporting period
Important discrepancy: The supplied filing is Sevion Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2015, filed May 14, 2015. It is not an Eloxx Pharmaceuticals filing or a 2014 Q3 report. The summary below reflects the filing actually provided.
Sevion was a development-stage biotechnology company focused on antibody discovery and therapeutics for cancer and immunological diseases. It changed its name from Senesco Technologies in September 2014. Interim financial statements are unaudited; the nine-month period is the fiscal year to date.
Financial results and position
| Metric | Three months ended March 31, 2015 | Nine months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $37,500 | $37,500 | $0 quarterly; $100,000 nine months |
| Operating expenses | $1.262 million | $17.195 million | $2.129 million quarterly; $5.571 million nine months |
| Net loss | $1.227 million | $17.157 million | $2.147 million quarterly; $5.551 million nine months |
| Basic and diluted loss per share | $(0.09) | $(1.24) | $(0.87) quarterly; $(2.21) nine months |
| Cash used in operating activities | $4.924 million for nine months | $3.650 million for nine months |
Revenue was minimal and derived from licensing or collaboration arrangements; the filing reports no meaningful revenue-based margin. Nine-month results included an $8.122 million goodwill impairment, a $2.291 million write-off of Factor 5A patents, and a $670,000 write-off of unused clinical-trial supplies. Cash operating burn is a more informative operating measure than net loss, which included these substantial noncash charges.
At March 31, 2015, cash and cash equivalents were $470,000, down from $6.111 million at June 30, 2014. Current assets were $598,000 and current liabilities $1.656 million, producing a $1.057 million working-capital deficit. Total liabilities were $5.714 million, including a $3.920 million deferred tax liability; the filing does not report material interest-bearing debt outstanding. Stockholders’ equity was $11.206 million. Cash used in investing was $717,000; there were no financing cash flows in the nine-month period.
Changes versus prior periods
- Quarterly net loss narrowed 42.8% year over year, mainly due to lower general and administrative and research and development costs. Quarterly R&D expense fell 75.7%, including a $443,000 gain from vendor debt forgiveness.
- Nine-month net loss increased 209.1% year over year, primarily from the goodwill and patent impairments, higher R&D spending, and inclusion of Fabrus, acquired in May 2014.
- Nine-month revenue fell from $100,000 to $37,500. The current-period amount was amortized deferred collaboration revenue.
- Cash declined by $5.641 million over the nine months, and operating cash use rose from $3.650 million to $4.924 million.
Outlook, management commentary, and risks
- Management stated that March 31 cash plus approximately $2.745 million of net proceeds from securities offerings closed May 1 and May 7, 2015 was expected to fund operations through at least November 30, 2015. Additional capital will be needed; management could not assure that financing or strategic transactions would be available on acceptable terms.
- The May offering generated approximately $3.0 million gross proceeds. Securities included common stock or convertible preferred stock and warrants; the preferred stock and warrants include conversion or exercise-price adjustment provisions. These terms, alongside outstanding options and warrants, create potential dilution. The offering also includes resale-registration deadlines and potential liquidated damages for missed deadlines.
- Sevion discontinued development of its Factor 5A/SNS01-T program after reviewing trial safety and efficacy results, reformulation costs, and limited funds; it said it would consider other potential uses of the technology. It also closed its New Jersey office, terminated its University of Waterloo research agreement, and reduced antibody-program spending pending financing or a strategic transaction.
- The company continued antibody discovery work and described a collaboration with a Janssen affiliate. Janssen received an option to license resulting candidates; Sevion could receive development and commercial milestones potentially totaling up to $125 million and low-single-digit royalties, but these amounts are contingent and not assured revenue.
- The filing identifies substantial going-concern risk from recurring losses, negative operating cash flows, minimal revenue, and limited cash. It notes the prior-year auditor’s going-concern explanatory paragraph and warns that failure to raise funds could require curtailing programs, licensing assets, pursuing a sale, or ceasing operations.
- Other material risks include clinical and regulatory uncertainty, dependence on third parties and key personnel, intellectual-property protection, competition, and a limited OTCQB trading market. Management reported disclosure controls were effective and no material change in internal controls during the quarter.
Key facts for investors to verify
- Confirm the issuer and period: the source is Sevion Therapeutics, Inc., quarter ended March 31, 2015—not Eloxx Pharmaceuticals or 2014 Q3.
- Review the May 2015 financing’s final proceeds, share and warrant counts, conversion and anti-dilution terms, registration deadlines, and resulting dilution.
- Assess whether cash runway assumptions remain valid and whether subsequent financing or licensing transactions were obtained; management’s stated runway ended at least November 30, 2015.
- Separate recurring cash operating burn from the period’s impairments and write-offs, and evaluate the status and economics of the Janssen collaboration.
- Verify the status of Factor 5A/SNS01-T, antibody-program spending, and any subsequent pipeline, clinical, or strategic changes.